Obesity-related hypertension

Ochsner Journal

Volumn 9, Issue 3, 2009, Pages 133-136

  Re, Richard N ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Hypertension; Obesity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RIMONABANT; TELMISARTAN;

ADRENERGIC SYSTEM; ANGIONEUROTIC EDEMA; DIABETES MELLITUS; DIET; DIURESIS; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RETENTION; WEIGHT REDUCTION;

EID: 70349640054     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Laragh JH. Presentation of the Harvey Award to Arthur C. Guyton. Am J Hypertens. 1989;2(7):573-574.
2. Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev. 2002;10(3):127-138.
3. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep. 2000;2(2):139-147.
4. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324(3):127-137.
5. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des. 2004;10(29):3621-3637.
6. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7, pt 1):694-698.
7. Victor RG, Shafiq MM. Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep. 2008;10(3):241-247.
8. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26(5):831-843. (Pubitemid 351540757)
9. Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care. 2002;25(11):2088-2097.
10. Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol. 2001;16(6):317-327.
11. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44-52.
12. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89(1):493-498.
13. Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol. 2008;20(suppl 1):110-115.
14. Sarzani R. Endocannabinoids, blood pressure and the human heart. J Neuroendocrinol. 2008;20(suppl 1):58-62. (Pubitemid 351552678)
15. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Brambilla G, Mancia G. Blood pressure lowering effects of rimonabant in obesity-related hypertension. J Neuroendocrinol. 2008;20(suppl 1):63-68. (Pubitemid 351559283)
16. Lavie CJ, Milani RV, Ventura HO, Cardenas GA, Mehra MR, Messerli FH. Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol. 2007;100(9):1460-1464. (Pubitemid 47576028)
17. Toprak A, Wang H, Chen W, Paul T, Srinivasan S, Berenson G. Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am J Cardiol. 2008;101(11):1621-1625.
18. Philip-Couderc P, Smih F, Hall JE, et al. Kinetic analysis of cardiac transcriptome regulation during chronic high-fat diet in dogs. Physiol Genomics. 2004;19(1):32-40. (Pubitemid 40039911)
19. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun. 2006;339(2):633-641. (Pubitemid 41739714)
20. Wenzel UO, Krebs C. Management of arterial hypertension in obese patients. Curr Hypertens Rep. 2007;9(6):491-497.
21. Mark AL. Weight reduction for treatment of obesity-associated hypertension: nuances and challenges. Curr Hypertens Rep. 2007;9(5):368-372.
22. Mark AL. Dietary therapy for obesity is a failure and pharmacotherapy is the future: a point of view. Clin Exp Pharmacol Physiol. 2006;33(9):857-862.
23. Re RN. The renin-angiotensin systems. Med Clin North Am. 1987;71(5):877-895.
24. Francischetti EA, Celoria BM, Francischetti A, Genelhu VA. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther. 2008;6(3):289-303.